Job UMC St Radboud - PhD Student Medical Oncology

The techniques you will perform include immunohistochemistry, in vitro cell assays, in vivo animal studies and preclinical imaging (PET, SPECT).
•You are expected to participate actively in the preclinical studies under supervision of senior researchers
•The PhD will be part of the Radboud Sarcoma Research Group, in which preclinical and clinical investigators work closely together
•This project will lead to a PhD thesis

A degree in (Medical) Biology
•Authorization to work with experimental animals in the Netherlands (art 9 certificate) and authorization to work with radioactivity (Stralingshygiëne Nivo 5b) is a plus
•Experience in and affinity for preclinical research and in vivo work is highly valued
•Our research requires a broad interest and good communication skills

Maximum all-in yearly salary on full time basis is € 33,340 gross.

Het Universitair Medisch Centrum St Radboud is een topkenniscentrum voor academische geneeskunde en gezondheidszorg. Kennis verbindt onderzoek, onderwijs en patiëntenzorg en vormt het hart van de organisatie. Vanuit ambitie en betrokkenheid geven ruim 8.500 medewerkers en 3.000 studenten inhoud aan de toekomst van gezondheidszorg en medische wetenschappen.

Gedreven door kennis, bewogen door mensen.

The department of Medical Oncology focuses on the development of novel diagnostic tools and cancer treatments in order to improve the life expectancy of cancer patients, while preserving a good quality of life. Within the RUNMC the department plays an important role in the Radboud Translational Oncology Program for targeted therapies (RTOP-TT). This multidisciplinary collaboration between the departments of Medical Oncology, Nuclear Medicine, Pathology, Radiotherapy, Surgery, Tumor Immunology and Radiology is established to combine knowledge and power from the different departments. Research is predominantly focused on the investigation of novel targeted cancer treatment in combination with the classical chemotherapy and radiotherapy together with advanced molecular imaging and microscopical analysis of tumor tissues.

Survival in bone sarcoma patients is still limited and new therapeutic options are awaited. An important new target for the treatment of these tumors is the insulin-like growth factor-1 receptor (IGF-1R), but so far there are no markers available to select patients for therapy.

The aim of this project will be to design an optimal treatment strategy in bone sarcomas, rationally positioning and incorporating the novel concept of IGF-1R targeting in current treatment strategies to enable individualization of therapy and consequently protect patients against the toxic effects of ineffective treatment and reduce unnecessary treatments. Sarcoma mouse models will be used for this work.

Mrs. prof. dr. W.T.A. van der Graaf, department of Medical Oncology
+31 (0)24 361 03 54

Mrs. dr. Y. Versleijen-Jonkers, department of Medical Oncology
+31 (0)24 361 88 97

Survival in bone sarcoma patients is still limited and new therapeutic options are awaited. An important new target for the treatment of these tumors is the insulin-like growth factor-1 receptor (IGF-1R), but so far there are no markers available to select patients for therapy. The aim of this project will be to design an optimal treatment strategy in bone sarcomas, rationally positioning and incorporating the novel concept of IGF-1R targeting in current treatment strategies to enable individualization of therapy and consequently protect patients against the toxic effects of ineffective treatment and reduce unnecessary treatments. Sarcoma mouse models will be used for this work.